Everycell's Effect on DNA Damage, Inflammation, and Stress
NCT02032693 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2014-05-23
Summary
The investigators are conducting this research because they want to determine if a dietary supplement, called Everycell™, has an effect on the functioning of the study participants' cells. The results of this research will be used to help develop additional strategies for trying to fight the effects of aging. The primary purpose of this study is to determine the effectiveness of Everycell™ compared to placebo (a pill that does nothing) on DNA damage, inflammation, stress, and related factors. Taking Everycell™ is not a medical prescription, treatment, or cure for any known disease or condition.
Helping patients' nutritional status is important to prevent the continued worsening of chronic diseases and also to counteract the effects of aging. Americans also have difficulties with compliance to prescription medications due to their toxicity and side effects. This study aims to learn more about how a dietary supplement may improve nutritional status and enable the body to normalize cellular functioning, which may improve quality of life. The results of this research will be used to determine if Everycell™ is beneficial for overall cellular health and to counteract the effects of aging.
Conditions
- Family Member
Interventions
- DIETARY_SUPPLEMENT
-
Everycell™
- OTHER
-
Placebo
Sponsors & Collaborators
-
CellHealth Institute
collaborator UNKNOWN -
University of Miami
lead OTHER
Principal Investigators
-
John Lewis, Ph.D. · University of Miami
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-12-31
- Primary Completion
- 2014-04-30
- Completion
- 2014-04-30
Countries
- United States
Study Locations
More Related Trials
-
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02100423 ·Status: COMPLETED ·Phase: PHASE2
-
Cocoa Supplementation, Inflammaging, and Epigenetic Aging
NCT05510375 ·Status: UNKNOWN ·Phase: PHASE4
-
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
NCT00365209 ·Status: COMPLETED ·Phase: PHASE2
-
Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
NCT00055978 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Selenomethionine and Myo-inositol(SOLOWAYS_TM) in Patients With Autoimmune Thyroiditis Carrying the DIO2 Thr92Ala Polymorphism
NCT06867913 ·Status: COMPLETED ·Phase: NA
-
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
NCT04866810 ·Status: SUSPENDED ·Phase: NA
-
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
NCT06097663 ·Status: COMPLETED ·Phase: PHASE2
-
Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
NCT00027976 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT
NCT04685525 ·Status: WITHDRAWN ·Phase: NA
-
Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease
NCT00541164 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
NCT00023621 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of [14C]-LY4065967 in Healthy Participants
NCT07039045 ·Status: COMPLETED ·Phase: PHASE1
-
Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
NCT00969085 ·Status: WITHDRAWN ·Phase: PHASE2
-
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
NCT05229588 ·Status: COMPLETED ·Phase: PHASE2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
NCT04079179 ·Status: RECRUITING ·Phase: PHASE2
-
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
NCT00052611 ·Status: COMPLETED ·Phase: PHASE2
-
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
NCT00088972 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
NCT06055894 ·Status: RECRUITING ·Phase: NA
-
Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients
NCT01269203 ·Status: WITHDRAWN ·Phase: PHASE2
-
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
NCT06028022 ·Status: RECRUITING ·Phase: PHASE2
-
Celecoxib in Treating Patients With Precancerous Lesions of the Mouth
NCT00014404 ·Status: COMPLETED ·Phase: PHASE2
-
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
NCT00953849 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
NCT00450736 ·Status: COMPLETED ·Phase: PHASE1
-
Celecoxib in Preventing Skin Cancer
NCT00025051 ·Status: WITHDRAWN ·Phase: PHASE2
-
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
NCT01014546 ·Status: TERMINATED ·Phase: PHASE1